Embecta Corp. — FY2023 Form 10-K
Reporting period: Fiscal year ended September 30, 2023. Although the request metadata says “2023 Q4,” this filing is an annual report; the supplied text does not provide a separate fourth-quarter results breakdown. Dollar amounts are in millions unless noted.
Business context
Embecta is a global medical-device company focused on diabetes care, primarily selling pen needles, insulin syringes and safety injection devices. It estimates its products are used by more than 30 million people in over 100 countries. Embecta completed its spin-off from Becton, Dickinson and Company (BD) on April 1, 2022 and is still transitioning certain services, distribution and operations from BD.
Financial performance
| Metric | FY2023 | FY2022 |
|---|---|---|
| Revenue | $1,120.8 | $1,129.5 |
| Gross profit / margin | $749.9 / 66.9% | $774.9 / 68.6% |
| Operating income | $221.5 | $309.6 |
| Net income | $70.4 | $223.6 |
| Diluted EPS | $1.22 | $3.89 |
| Cash provided by operating activities | $67.7 | $412.2 |
| Capital expenditures | $26.5 | $23.6 |
- Revenue declined $8.7, or 0.8%. A $26.5 unfavorable foreign-exchange impact and $1.9 lower contract-manufacturing revenue were partly offset by $19.7 of favorable price and volume changes. U.S. revenue was $601.4; international revenue was $519.4.
- Cost of products sold rose 4.6% to $370.9, attributed mainly to inflation in raw materials, freight, labor and overhead, as well as higher post-separation cannula costs. Gross margin fell 1.7 percentage points.
- Operating income fell $88.1. Selling and administrative expense increased $46.5, R&D increased $18.3, and other operating expenses increased $54.7; the prior-year period included a larger $58.9 impairment charge, compared with $2.5 in FY2023. FY2023 other operating expenses included $92.7 of separation and stand-up costs, including approximately $5.6 of severance.
- Net income decreased $153.2, while net interest expense increased to $107.0 from $46.2, reflecting a longer period with debt outstanding and higher rates on variable-rate borrowings. The effective tax rate rose to 33.4% from 12.9%.
- Operating cash flow declined to $67.7. Working-capital and other cash uses included a $28.8 inventory increase, a $23.2 increase in amounts due from/due to BD, and a $14.2 increase in prepaid expenses and other. Cash and cash equivalents were $326.5 at year-end, down $4.4.
Debt, liquidity and capital allocation
At September 30, 2023, principal debt was $1,635.8: a $935.8 SOFR-based term loan, $500.0 of 5.00% senior secured notes due 2030 and $200.0 of 6.75% senior secured notes due 2030. Reported total debt, including the current portion and net of debt costs and discounts, was $1,603.4; weighted-average debt cost was 7.1%. The $500.0 revolving credit facility was undrawn. The company was in compliance with its debt covenants. Cash was $326.5; the filing states management believes cash, operating cash flow and available revolver capacity can fund foreseeable needs.
FY2023 financing cash uses included $34.4 of dividends and $9.5 of debt principal payments. The company paid four quarterly dividends of $0.15 per share during FY2023; a further $0.15 dividend was declared after year-end. Management cautions that future dividend timing and amounts are discretionary and subject to debt covenants and other factors.
Changes, outlook and material risks
- Standalone transition: Separation-related costs and the transition away from BD contributed to higher expenses. Embecta expects FY2024 stand-up costs of a similar nature to be lower than FY2023, but still anticipates such costs. It is implementing its own ERP in phases; the first phase began in the fourth quarter of FY2023.
- BD dependence: BD supplies cannulas and provides transitional services and distribution support. Certain services were extended in limited markets, subject to BD obtaining a supplemental IRS private letter ruling; the filing says there is no assurance it will be obtained. The logistics services agreement was extended through March 31, 2024, while a limited extension of certain services may run through November 1, 2024, subject to the ruling.
- Interest-rate exposure: Management expects FY2024 interest expense on variable-rate debt to rise if rates remain at or above current levels. A 100-basis-point rate change would affect annualized term-loan interest expense by approximately $9.4.
- Product and customer concentration: Pen needles generated $912, or 81% of FY2023 revenue. The three largest distributors represented approximately 40.2% of worldwide gross sales. Pricing pressure, payer coverage decisions, lower-cost competitors and new diabetes therapies that delay or reduce insulin use could weigh on demand and margins.
- Supply and operational transition: BD controls cannula production and related intellectual property, and the supply agreement limits annual purchases. Regulatory approvals delayed local separation transfers in China, Mexico and Italy; a temporary manufacturing suspension in China had been initiated. Embecta also cites potential disruption from supplier concentration, manufacturing, sterilization and transition-service changes.
- Product development: An insulin patch pump for people with Type 2 diabetes is in development, with a related collaboration to develop an interoperable glucose controller. No FDA application for the pump had been submitted as of the filing; approval, commercialization and returns are uncertain.
- Other risks and contingencies: The filing highlights foreign exchange, inflation, commodity and energy costs, geopolitical disruption, regulation, cybersecurity, tax and separation-related indemnification risks. It reported no material legal proceedings as of September 30, 2023 and no unresolved SEC staff comments.
The filing provides no quantified revenue or earnings guidance. The financial statements received an unqualified audit opinion, and management and the auditor concluded internal control over financial reporting was effective as of September 30, 2023.
Investor verification priorities
- Track whether FY2024 operating cash flow recovers and whether inventory, BD-related balances and other working-capital movements normalize.
- Monitor the transition from BD services, ERP implementation, required product rebranding and regulatory/license transfers, including the status of the supplemental private letter ruling and the China manufacturing transition.
- Assess whether pricing and volume can offset foreign-exchange effects, input-cost inflation and higher cannula and distributor costs.
- Review variable-rate debt costs, covenant headroom, scheduled principal payments and the sustainability of dividends against cash generation.
- Follow the patch-pump development and regulatory timeline, and test the company’s reliance on pen needles and a small number of distributors and customers.